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trated with an example that highlights pitfalls involved with more simplistic ap-
proaches.
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CLOSING THE GAP BETWEEN THE FORMULATION AND IMPLEMENTATION OF
CLINICAL PRACTICE GUIDELINES BASED ON EVIDENCE
Gordillo AM, Eslava-Schmalbach J, Amaya Arias AC
Universidad Nacional de Colombia, Bogotá, Colombia
OBJECTIVES: To describe the theoretical approach suggested to close the gap be-
tween recommendations and implementation of clinical practice guidelines
(CPG’s) in Colombia, called harmonization of CPG’s with Public Policy. METHODS:
Perspective paper. A theoretical approach is suggested to harmonize CPG’s recom-
mendationswith public policy. RESULTS: Public policies often don=t get the desired
results, because there is a gap between the decision and the reality. There is a
conceptual and temporal separation between policy formulation and implemen-
tation of decisions, CPG’s are tools to improve quality in the delivery of health
services. However a process od harmonization between recommendations and
implementation with public policy is requested. For this a process of three phases
should be developed: 1) To do a review of existing regulations on health and on the
specific issue of the CPG to harmonize the current policy with recommendations
and identify barriers to the implementation process; 2) To adjust recommenda-
tions of CPG’s to eliminate the barriers encountered with the standards; 3. To state
a negotiation processwith all actors involved in the implementation of the CPG’s at
different levels of care, to generate commitment with them, proposals for changes
in policy and / or administrative, and if it is necessary, to remove barriers
CONCLUSIONS:Harmonization of CPG’s with public policy is a fundamental tool to
improve their implementation. Three phases are proposed. Negotiation could be
the most important one.
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SOCIETAL PERSPECTIVE IN ECONOMIC EVALUATION: CONFUSIONS AND
HIRA’S RECOMMENDATION
Bae S, Lee S, You MY
Health Insurance Review & Assessment Service, Seoul, South Korea
BACKGROUND: Current HIRA’s guideline recommends that economic evaluation
(EE) analysis should take societal perspective, yet the inconsistency in current
guideline has beennoted by the industry side. The purpose of this study is to review
current theoretical trends and discuss the needs of updating HIRA’s current
recommendations.METHODS: To identify the needs of EE guideline revision, HIRA
has reviewed currently updated foreign EE guidelines, and discussed recent theo-
retical trends. In addition, survey results from pharmaceutical companies as well
as decision makers regarding current recommendation were considered. Experts
meetings and working group meetings with industry people were held to share
each party’s perspectives. RESULTS: Pharmaceutical industry suggested that cur-
rent recommendation of taking societal perspective while submitting indirect cost
(especially productivity cost) separately is confusing. Canada (CADTH) has recently
updated its perspective as “publicly funded health care system”, and UK (NICE) has
recommended to take payer(NHS and PSS)’s perspective. Inconsistencies in soci-
etal perspective have also discussed in previous studies and ISPOR consensus
paper. CONCLUSIONS: Given that EE guideline should provide clear minimum
standards for submission parties, a need to clarify current “societal” perspective
has been agreed by relevant parties. “Limited” societal perspective has been pro-
posed to reduce unnecessary confusionswhile reflecting current practice patterns.
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PREVALENCE-BASED VERSUS INCIDENCE-BASED ECONOMIC EVALUATIONS
FOR THE ASSESSMENT OF NEW HEALTH CARE INTERVENTIONS
Mauskopf JA
RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVES: To compare the usefulness to decision makers of prevalence-based
versus incidence-based economic evaluations of new health care interventions
METHODS: Comparison of evaluation methods by: population included, time ho-
rizon, outcomes measured, adherence to economic principles, and usefulness to
decision makers. RESULTS: An incidence-based economic evaluation follows a
disease cohort for the duration of the disease and estimates discounted costs and
health gains with alternative interventions. The cost-effectiveness ratio is based
on individual utility maximization and provides information to decision makers
about the efficiency of a new healthcare intervention compared to societal willing-
ness to pay for health gains. It does not estimate annual budget impacts. It gener-
ally does not capture indirect effects on the population. A prevalence-based eco-
nomic evaluation provides estimates of costs and health benefits for the total
population for one year or cumulated over a longer time horizon. The estimated
ratio of cumulative costs and health benefits is not based on economic principles.
Appropriate threshold values for these ratios are those based on a percentage of
Gross Domestic Product as recommended by the World Health Organization. The
prevalence-based cost-effectiveness ratio provides information to decisionmakers
on the affordability of the intervention and the value for money over the selected
time horizon. A prevalence-based analysis can take into account indirect effects of
health care interventions and is, therefore, frequently used for economic evalua-
tions of vaccine programs. CONCLUSIONS: Prevalence-based economic evalua-
tions might be of greater use to health care decision makers than incidence-based
evaluations because, in addition to estimates of value for money, they provide
estimates of affordability and allow comparison of all types of health care inter-
ventions. Threshold values based on economic principles, however, are not appli-
cable for ratios generated using the prevalence-based approach.
DISEASE-SPECIFIC STUDIES
DIABETES/ENDOCRINE DISORDERS – Clinical Outcomes Studies
PDB1
COMPARING HYPOGLYCEMIA RATES FOR TYPE 2 DIABETES PATIENTS
TREATED WITH SAXAGLIPTIN VERSUS SULFONYLUREA: USING CLAIMS DATA
TO REPLICATE A CLINICAL TRIAL
Curkendall SM1, Zhang B2, Lenhart G3, Thomson EE1, Bell KF2, Graham JP2
1Thomson Reuters, Washington, DC, USA, 2Bristol-Myers Squibb Company, Plainsboro, NJ, USA,
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OBJECTIVES: A lower rate of hypoglycemia occurred in a Phase 3 trial in T2DM
patients receiving saxagliptin compared to glipizide (sulfonylurea (SU)) added to
metformin. The clinical trial included patient-reported and physician-reported hy-
poglycemia events. The objective of this study was to compare the rates of hypo-
glycemia events that required medical attention in actual clinical practice.
METHODS: MarketScan health care claims data was used to identify patients who
initiated saxagliptin or SU. During the 6 months prior to initiation, patients were
required to have a prescription (Rx) for metformin and no saxagliptin, SU, or other
diabetes Rx. Patients were followed for 4 months to assess the rates of hypoglyce-
mia. During follow-up, patients were required to have at least onemoremetformin
Rx and one additional saxagliptin/SU Rx and no other diabetes Rx. A hypoglycemia
event was defined as a diagnosis of hypoglycemia on an outpatient or emergency
room claim or principal diagnosis on a hospital claim or an outpatient glucagon
injection. SU patients were matched to saxagliptin patients (5 to 1) using propen-
sity scores. The rate ratio was further adjusted for covariates that were not bal-
anced between the matched cohorts using a Poisson regression model. RESULTS:
There were 1,567 saxagliptin, 21,025 SU, and 7,835 propensity-matched SU pa-
tients. The rate of hypoglycemia in the saxagliptin cohort was 1.74 per 100 PY
versus 6.68 in the SU cohort (rate ratio 0.31, 95% CI: 0.14 – 0.60) and 4.45 per 100 PY
in thematched SU sub-group (rate ratio 0.39, 95% CI: 0.17 – 0.77). After multivariate
adjustment, the rate ratio was 0.37 (95% CI: 0.19 – 0.74). CONCLUSIONS: In real
world practice, as was demonstrated in a randomized controlled trial, saxagliptin
patients had a lower risk of hypoglycemia than SU when added to metformin.
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VITAMIN B AND/OR ITS DERIVATIVES FOR DIABETIC KIDNEY DISEASE: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Raval A1, Thakker D2, Rangoonwala A2, Gor DM3
1West Virginia University, Morgantown, WV, USA, 2Shrimati Kaumudiniben Health Outcome
Research Group (SKHORG), Dhrangadhra, Gujarat, India, 3Nirma University, Ahmedabad,
Gujarat, India
OBJECTIVES:To assess the benefits andharms of vitamin B and/or its derivatives in
patientswith diabetic kidney disease (DKD).METHODS:Wesearched the Cochrane
Renal Group’s Specialized Register CENTRAL; MEDLINE OVID SP; Hand searching of
renal journals and conference proceedings; EMBASE OVID SP; the International
Clinical Trials Register (ICTRP) Search Portal & ClinicalTrials.gov. Randomized con-
trolled trials (RCTs) comparing vitamin B and/or its derivatives with placebo, no or
active treatment, in patients with DKD were included. RESULTS: Out of 56 identi-
fied studies, four studies were found to be suitable for inclusion. A total of 745
participants were randomized to either vitamin B derivatives (benfotiamine (300
mg TID), thiamine (300 mg OD), vitamin B12 (500 mg OD), folic acid (2.5 mg OD),
vitamin B6 (25 mg OD)) or placebo or active control. Treatment duration ranged
from 3 months to 36 months. We found that none of those derivatives improved
kidney function: improved creatinine clearance (Mean difference (MD) 2.00, 95% CI
-21.78 to 25.78, P 0.87), decreased serum creatinine level (MD 1.00, 95% CI -7.88 to
9.88, P  0.83), reduce level of urinary albumin excretion level (MD: -16.75, 95% CI
-103.44 to 69.94, P 0.70), improved the glomerular filtration rate (MD: -7.00, 95% CI
-22.33 to 8.33, P  0.37) significantly compared to placebo or active control. In
addition,we found that risk ofmyocardial infarction, stroke, revascularization, and
all-cause mortality, in the B-vitamin combination therapy group was increased
(Risk Ratio 1.85, 95%CI 0.99 to 3.45, P 0.05).We also found no significant difference
between vitamin B combination therapy and control group for serious adverse
events, and one or more adverse events. CONCLUSIONS: We did not find any
improvement in kidney function, following use of vitamin B preparation. These
findings require confirmation from high quality randomized trials.
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RISK OF COMPLICATIONS IN TYPE II DIABETIC PATIENTS WITH RENAL
IMPAIRMENT: AN ANALYSIS OF THE RAMQ DATABASE
Lachaine J1, Beauchemin C1, Flavin J2
1University of Montreal, Montreal, QC, Canada, 2Boehringer Ingelheim Canada Ltd, Burlington,
ON, Canada
OBJECTIVES: Chronic kidney disease is often associated with type II diabetes mel-
litus (T2DM). Patients with T2DM and chronic renal failure are at higher risk of
developing hypoglycemia or metabolic acidosis. The purpose of this study was to
identify treatment patterns in T2DM patients with chronic renal failure and to
estimate the risk of developing complications. METHODS: This study examined
data on patients covered by the Quebec provincial drug reimbursement program
(RAMQ) who had a diagnosis of diabetes, had used a hypoglycemic agent, and had
a diagnosis of chronic renal disease in the period from January 2005 to December
2010. A 1:1 control group of patients with diabetes and without renal disease,
matched for age and gender, was also created. Patients’ characteristics and drug
utilization patterns were analyzed and the risks of experiencing hypoglycemia or
metabolic acidosis were estimated. RESULTS: A total of 4889 patients who had a
diagnosis of diabetes with chronic renal failure were included in this cohort. Aver-
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age age was 69.2 years (SD10.1) and the proportion of men was slightly higher
(54.4%). The hypoglycemia incidence was higher in patients with than without
renal insufficiency (10.8% vs. 3.6%; p0.001). Similarly, the metabolic acidosis in-
cidencewas higher in patients with thanwithout renal insufficiency (1.9% vs. 0.9%;
p0.001). Renal insufficiency in diabetic patients was associated with increased
hypoglycemia [OR: 3.3 (95% CI: 2.8 – 3.9)], and metabolic acidosis [OR: 2.2 (95% CI:
1.5 – 3.2)].CONCLUSIONS:A significant proportion of diabetic patientswith chronic
renal failure experienced hypoglycemia or metabolic acidosis. Treatment strate-
gies for these patients that minimize the risk of these complications should be
considered.
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CONDUCT OUTCOMES RESEARCH IN CHINA - ADDRESSING CHALLENGES IN
DATA QUALITY CONTROL
Zhang D1, Ji L2, Hu D2, Zeng Y3, Zhang Z3
1VitalStrategic Research Institute, Berwyn, PA, USA, 2Peking University People’s Hospital,
Beijing, China, 3VitalStrategic Research Institute, Shanghai, Shanghai, China
OBJECTIVES: In China, an estimated 90 million adults are diabetic. An out-patient
clinic physician in a comprehensive hospital sees an average of 50 patients per day.
Patients but not physicians maintain the medical records. Investigators are not
used to electronic data acquiring systems. All these factors present challenges for
conducting quality outcomes research. We recently conducted “Nationwide As-
sessment of Cardiovascular Risk Factors in Chinese Patients with Type 2 Diabetes”,
whichwas aimed to enroll 25000 non-institutional patients nation-wide. In order to
ensure high quality and efficiency of the study, a multifaceted data quality control
process was implemented and evaluated. METHODS: For enrolled patients who
signed informed consent form, investigators were first required to report the orig-
inal patient information on a “Patient Record Form” which served as source docu-
ments, and subsequently to enter the data into aweb-based electronic data capture
system (VitalEDC, VSRI), which performs instantaneous edit checks and generates
real time data query. All investigational sites received frequent onsite monitoring
and auditing when frequent data query occurred or when 50% enrollment
achieved. Additionally, a 10% of the patient records at each site were randomly
selected for a remote source document verification (rSDV). RESULTS: A total of 734
investigators from 103 hospitals across 6 regions of China participated in this
study, and 25817 patientswere enrolledwithin 8months. Among enrolled patients,
100% the data were retrieved, 4,590,00 data records were evaluated, over 3000
unique querieswere generated, only 1.5% (377 out of 25,817) of the patients’ records
were excluded from analyses due to unexplainable queries of pre-defined key
information. CONCLUSIONS: The large sheer volume and rising epidemic of car-
diometabolic and other chronic diseases demand well controlled epidemiological
and comparative effectiveness research in China. Despite challenges, multifaceted
measures of quality control could yield relatively satisfactory outcomes.
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EFFICACY AND SAFETY OF LIRAGLUTIDE 1.2MG AND EXENATIDE 10MCG
TWICE DAILY IN TYPE 2 DIABETES MELLITUS: A SYSTEMTIC REVIEW AND
META-ANALYSIS
Ye Q1, Ploug UJ2
1Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China, 2Novo Nordisk A/S, Søborg,
Denmark
OBJECTIVES:To systematically examine the efficacy and safety of liraglutide 1.2mg
once-daily and exenatide 10mcg twice daily indirectly using meta-analysis of ran-
domized controlled trials (RCTs) involving a common comparator. METHODS: A
systematic review of the literature andmeta-analysiswas conducted. PUBMED and
MEDLINE (January 2000 – July 2011) were searched to identify English-language
randomized trials. Keywords included type 2 diabetes, liraglutide or exenatide, and
randomized controlled trials. Inclusion criteria were RCTs 12 weeks in duration,
type 2 diabetes patients18 years old, involving liraglutide 1.2mg once daily or
exenatide 10mcg twice daily. Meta-analysis was conducted for the following out-
comes: change from baseline in HbA1c, systolic blood pressure, weight and the
number of hypoglycemic episodes. Data were extracted and tabulated by two in-
dependent reviewers and differences were solved by consensus. 41 RCTs were
identified and 16 RCTswere included for further review. Only 10 RCTswith placebo
as common comparators had sufficient information andwere included in the anal-
ysis. Weighted mean differences (WMD) and their 95% confidence intervals were
calculated as appropriate. STATA 11.0 (StataCorp, College Station, Tex) was used to
perform the meta-analysis. RESULTS: Liraglutide 1.2mg once daily reduced HbA1c
1.10% more than placebo (p0.001); exenatide 10mcg twice daily reduced HbA1c
0.60% more than placebo, but not statistically significant (p0.723); liraglutide
1.2mg reduced weight 0.18kg more than placebo (p0.060),and exenatide reduced
weight 0.53kg more than placebo (p0.084); The rate of moderate hypoglycemia
associated with liraglutide 1.2mg was 2.93% in comparison to placebo; The rate of
moderate hypoglycemia associated with exenatide 10mcg was 9.22% in compari-
son to placebo. CONCLUSIONS: Indirect comparison of liraglutide 1.2mg once daily
and exenatide 10mcg twice daily suggest that in comparison to exenatide 10mcg,
liraglutide 1.2mg provided greater improvement in HbA1c, with fewer hypoglyce-
mia episodes.
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ANGIOTENSIN RECEPTOR BLOCKERS AND RISK OF CARDIOVASCULAR DEATH
IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Phung OJ, Sakharkar PR, Law AV
College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA
OBJECTIVES: Angiotensin Receptor Blockers (ARBs) are indicated for the preven-
tion and treatment of kidney disease in patients with Type 2 Diabetes Mellitus
(T2DM), with established efficacy for nephropathy outcomes. Randomized Con-
trolled Trials (RCTs) have also shown the benefit of using ARBs on cardiovascular
outcomes in patients with T2DM. Results from the ROADMAP trial raised concerns
of increased risk of cardiovascular death with olmesartan. Currently available
ARBs differ in terms of potency and surmountable versus insurmountable block-
ade; therefore, not all of them provide the same benefits and harms. In the absence
of published direct comparative studies, however, an indirect comparison among
these agents is necessary to inform clinical decisionmaking.METHODS:A system-
atic literature search was conducted in PubMed and Cochrane Central Register of
Controlled Trials through September 2011 for RCTs evaluating ARBs in patients
with T2DM. Outcomes of interest were cardiovascular death, all-cause mortality,
and cardiovascular morbidity and mortality. Outcomes were initially pooled using
standard random-effects methods producing odds ratios (OR) and 95% confidence
intervals (CI). Adjusted indirect comparisons between agents using pooled esti-
mateswere thenperformedusing Song’smethodwhen a common comparatorwas
available, typically a placebo. RESULTS:A total of 10,833 patients from 7 RCTswere
analyzed. Compared to olmesartan, candesartan offered statistically significant
protection against cardiovascular death (OR 0.14, 95%CI 0.03 - 0.72), while irbesar-
tan trended towards protection (OR 0.22, 95%CI 0.05 - 1.02). No significant differ-
ence was found between candesartan and irbesartan in cardiovascular death (OR
0.64, 95%CI 0.31 to 1.34). No significant differences were found between any agents
for all-cause mortality or cardiovascular morbidity or mortality. CONCLUSIONS:
Differences in outcomes may exist between ARBs in patients with T2DM, so head-
to-head clinical trials are required to confirm the findings of this adjusted indirect
comparison analysis.
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DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Ye Q1, Ploug UJ2
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OBJECTIVES:Comparing the efficacy and safety of liraglutide 1.2mg once dailywith
other hypoglycemic agents in adults with type 2 diabetes through systematic re-
view and meta-analysis of randomized controlled trials. METHODS: A systematic
review of the literature and meta-analysis was conducted. PUBMED and MEDLINE
(Jan 2000 – July 2011) were searched to identify English-language randomized con-
trol trials. Keywords included: type 2 diabetes, liraglutide, and randomized con-
trolled trials. Inclusion criteria were: RCTs 12 weeks in duration, type 2 diabetes
patients 18 years old, comparing liraglutide 1.2mg once daily with placebo or
other active diabetic medications. Meta-analysis was conducted for the following
outcomes: change from baseline in HbA1c, systolic blood pressure and weight as
well as the number of hypoglycemic episodes. Two reviewers independently as-
sessed trials for inclusion and extracted data. Differences were solved by consen-
sus. 41 RCTswere identified and 5 RCTsmet the inclusion criteria. The comparators
were rosiglitazone, glimepiride, placebo and sitagliptin, and were collectively de-
fined as the “comparators”. HbA1c, weight and systolic blood pressure were ana-
lyzed as weighted mean differences (WMD), and the number of hypoglycemic ep-
isodes as relative risks (RR). STATA 11.0 (StataCorp, College Station, Tex) was used
to perform themeta-analysis. RESULTS: In comparison to the “comparator group”,
patients receiving liraglutide 1.2mg reduced HbA1c by 0.54%more (95% confidence
interval, CI-0.81 to -0.28, p0.001); weight loss with liraglutide 1.2mg was 0.54 kg
more than with comparators ( 95% CI-0.72 to -0.36, p0.001); liraglutide 1.2mg
reduced systolic pressure 0.14mmHg more than the comparators (95% CI-0.22 to
-0.06, p0.001); Hypoglycemia episodeswere similar between liraglutide 1.2mg and
the comparators (RR0.86, 95%CI: 0.39 to 1.93, p0.722). CONCLUSIONS: Liraglu-
tide 1.2mg once daily is effective in glycemic control, has the advantage of promot-
ing weight loss and reducing systolic blood pressure versus the comparators for
treating type 2 diabetes.
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THE EFFECT OF DAPAGLIFLOZIN ON HEDIS PERFORMANCE MEASURES OF
HBA1C IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Bell K1, Hardy E2, De Bruin T2, Wei L1, Martin P2, Ptaszynska A1
1Bristol-Myers Squibb Company, Princeton, NJ, USA, 2AstraZeneca, Wilmington, DE, USA
OBJECTIVES:Healthcare Effectiveness Data and Information Set (HEDIS) measures
are used to rate health plan performance; HEDIS quality of diabetes care measures
include glycated hemoglobin (HbA1c) categories 7% or 8%, which define good
control, and 9%, which defines poor control. Dapagliflozin, a sodium glucose
cotransporter 2 inhibitor, is under clinical development for the treatment of type 2
diabetes mellitus (T2DM). We assessed the effect of dapagliflozin on achieving
HbA1c outcomes by HEDIS categories.METHODS: Pooled data for dapagliflozin 10
mg/day (N1066) vs placebo (N1257) from nine 24-week, phase 3, randomized,
placebo-controlled trials in patients with T2DM, including monotherapy
(NCT00528372, NCT00736879) and add-on to metformin (NCT00528879,
NCT00855166), glimepiride (NCT00680745), pioglitazone (NCT00683878), or insulin
(NCT00673231), or initial combination with metformin (NCT00859898,
NCT00643851) trials, were analyzed. Adjusted mean change in HbA1c from base-
line to week 24 with dapagliflozin vs placebo was determined for patients with
baseline HbA1c of 8%, 8% to9%, and 9%. Additionally, the proportions of
patients achieving HEDIS HbA1c categories of 7%, 8%, and 9% were assessed.
RESULTS: Placebo-subtracted adjusted mean changes in HbA1c (95% CI) at 24
weeks with dapagliflozin were –0.45% (–0.56%, –0.33%), –0.62% (–0.75%, –0.48%),
and –0.78% (–0.93%, –0.63%) for patients with baseline HbA1c 8%, 8% to9%,
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